Avanafil CAS: 330784-47-9
Product Name: Avanafil
CAS: 330784-47-9
MF: C23H26ClN7O3
MW: 483.95
mp: 150-152°C
density: 1.372
Assay: 99% min
storage temp: Refrigerator
Appearance: White to Off-White Cyrstalline Solid
Usage:
It is a development of the phosphodiesterase type 5 inhibitors, for the treatment of male sexual dysfunction, at present in the America, EU and
Japan have completed phase II clinical trials, phase III clinical trials will start. The product is composed of Japanese Tanabe Pharma Company and
VIVUS company development. In addition to oral dosage forms, VIVUS company is also developing Avanafil urethral administration, for not responding
to oral dosage forms of patients.
Avanafil is a potent, highly selective phosphodiesterase 5 inhibitor, in vitro experiments showed that the selectivity of phosphodiesterase 5
stronger than sildenafil. The compound dear compliance weak against other phosphodiesterase, and effect of adenosine receptor decreased,
suggesting that the cardiovascular effects of avanafil should be weaker than sildenafil. Pre clinical study showed that avanafil and organic
nitrate drugs taken in combination to reduce its on blood pressure was significantly weaker than sildenafil and nitrate drugs with clothes.
Moreover, avanafil inhibition of phosphodiesterase 6 is very weak, the relevant visual disturbance suppression may the enzyme phosphodiesterase 5
inhibitor induced and other.
Dosage :
For most individuals, the recommended starting dose of avanafil is 100 mg per day taken about 30 minutes before sexual activity. Depending on the
adequacy of the response or side effects, the dose may be increased to 200 mg or decreased to 50 mg a day. Individuals who are taking medications
that moderately increase the blood levels of avanafil should not exceed a total dose of 50 mg in 24 hours.
